Charles A. Rowland Jr.

CIK: 0001383292

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (5.6%)

Position reduction

Option Exercises (M)3 (16.7%)

Derivative conversions

Awards (A)6 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)8 (44.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

GBIO

Generation Bio Co.

Director

VKTX

Viking Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (18 total)

GBIO
Generation Bio Co.
Feb 9, 2026
Disposition(D)
Stock Option (right to buy)
Direct
4.2K shares-
GBIO
Generation Bio Co.
Feb 9, 2026
Tender Offer(U)
Direct
53.5K shares-
GBIO
Generation Bio Co.
Feb 9, 2026
Disposition(D)
Stock Option (right to buy)
Direct
6K shares-
GBIO
Generation Bio Co.
Feb 9, 2026
Disposition(D)
Stock Option (right to buy)
Direct
2.5K shares-
GBIO
Generation Bio Co.
Feb 9, 2026
Disposition(D)
Stock Option (right to buy)
Direct
1.9K shares-
GBIO
Generation Bio Co.
Feb 9, 2026
Disposition(D)
Stock Option (right to buy)
Direct
1.5K shares-
GBIO
Generation Bio Co.
Feb 9, 2026
Disposition(D)
Stock Option (right to buy)
Direct
5.2K shares-
GBIO
Generation Bio Co.
Feb 9, 2026
Disposition(D)
Stock Option (right to buy)
Direct
3K shares-
VKTX
Viking Therapeutics, Inc.
Jan 2, 2026
Award(A)
Direct
3.2K shares-
VKTX
Viking Therapeutics, Inc.
Oct 27, 2025
Exercise(M)
Stock Option (Right to Buy)
Direct
22K shares-
VKTX
Viking Therapeutics, Inc.
Oct 27, 2025
Sale(S)
Direct
60K shares at avg. $35.57$2.1M
VKTX
Viking Therapeutics, Inc.
Oct 27, 2025
Award(A)
Direct
22K shares at avg. $4.88$107K
VKTX
Viking Therapeutics, Inc.
Oct 27, 2025
Award(A)
Direct
22K shares at avg. $5.80$128K
VKTX
Viking Therapeutics, Inc.
Oct 27, 2025
Award(A)
Direct
16K shares at avg. $4.48$72K
VKTX
Viking Therapeutics, Inc.
Oct 27, 2025
Exercise(M)
Stock Option (Right to Buy)
Direct
16K shares-
VKTX
Viking Therapeutics, Inc.
Oct 27, 2025
Exercise(M)
Stock Option (Right to Buy)
Direct
22K shares-
GBIO
Generation Bio Co.
Jun 4, 2025
Award(A)
Stock Option (right to buy)
Direct
30K shares-
VKTX
Viking Therapeutics, Inc.
Jan 2, 2025
Award(A)
Stock Option (Right to Buy)
Direct
18.8K shares-

		Type	Shares	Price		Ownership
Feb 9, 2026	GBIO Generation Bio Co.	Disposition(D) Stock Option (right to buy)	4,246	-	-	Direct
Feb 9, 2026	GBIO Generation Bio Co.	Tender Offer(U)	53,475	-	$0	Direct
Feb 9, 2026	GBIO Generation Bio Co.	Disposition(D) Stock Option (right to buy)	6,000	-	-	Direct
Feb 9, 2026	GBIO Generation Bio Co.	Disposition(D) Stock Option (right to buy)	2,500	-	-	Direct
Feb 9, 2026	GBIO Generation Bio Co.	Disposition(D) Stock Option (right to buy)	1,920	-	-	Direct
Feb 9, 2026	GBIO Generation Bio Co.	Disposition(D) Stock Option (right to buy)	1,500	-	-	Direct
Feb 9, 2026	GBIO Generation Bio Co.	Disposition(D) Stock Option (right to buy)	5,200	-	-	Direct
Feb 9, 2026	GBIO Generation Bio Co.	Disposition(D) Stock Option (right to buy)	3,000	-	-	Direct
Jan 2, 2026	VKTX Viking Therapeutics, Inc.	Award(A)	3,150	-	$0	Direct
Oct 27, 2025	VKTX Viking Therapeutics, Inc.	Exercise(M) Stock Option (Right to Buy)	22,000	-	-	Direct
Oct 27, 2025	VKTX Viking Therapeutics, Inc.	Sale(S)	60,000	$35.57	$2,134,278	Direct
Oct 27, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	22,000	$4.88	$107,360	Direct
Oct 27, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	22,000	$5.80	$127,600	Direct
Oct 27, 2025	VKTX Viking Therapeutics, Inc.	Award(A)	16,000	$4.48	$71,680	Direct
Oct 27, 2025	VKTX Viking Therapeutics, Inc.	Exercise(M) Stock Option (Right to Buy)	16,000	-	-	Direct
Oct 27, 2025	VKTX Viking Therapeutics, Inc.	Exercise(M) Stock Option (Right to Buy)	22,000	-	-	Direct
Jun 4, 2025	GBIO Generation Bio Co.	Award(A) Stock Option (right to buy)	30,000	-	-	Direct
Jan 2, 2025	VKTX Viking Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	18,800	-	-	Direct

1-18 of 18 transactions

About Rowland Charles A Jr

Rowland Charles A Jr (SEC CIK 0001383292) files insider reports with the SEC as Director of Generation Bio Co. (GBIO) and Director of Viking Therapeutics, Inc. (VKTX).

Signal8 holds 5 ownership filings by Rowland Charles A Jr, all Form 4s, filed between Jan 6, 2025 and Feb 9, 2026. Those filings report 18 transactions, from Jan 2, 2025 to Feb 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rowland Charles A Jr's filings is in CAMBRIDGE, MA.

Recent filings by Rowland Charles A Jr

Feb 9, 2026: Disposition to issuer transaction of GBIO derivative securities (Form 4, code D).
Feb 9, 2026: Tender of shares transaction of GBIO shares (Form 4, code U).
Feb 9, 2026: Disposition to issuer transactions of GBIO derivative securities (6 lines, Form 4, code D).
Jan 2, 2026: Grant or award of VKTX shares (Form 4, code A).
Oct 27, 2025: Option exercise of VKTX derivative securities (Form 4, code M).

Other insiders filing for Generation Bio Co. (GBIO)

How to read Form 4 transaction codes